Berlin - Delayed Quote EUR

Faron Pharmaceuticals Oy (4FR.BE)

2.1900

-0.0200

(-0.90%)

As of 12:56:05 PM GMT+1. Market Open.

Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announced full analysis of the positive Phase 2 interim readout presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.

PR Newswire last month

FARN.L
Faron Pharma secures UK innovation passport for blood cancer immunotherapy

The MHRA has also granted approval to Faron Pharmaceuticals to conduct the BEXMAB trial of Clevegen in the UK.

Pharmaceutical Technology last month

^YH206

GLDAF
Faron Pharmaceuticals reports positive data from MDS trial

The combination treatment was found to be well tolerated without demonstrating any dose-limiting toxicity.

Clinical Trials Arena 8 months ago

^YH206
Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Dr. Markku Jalkanen and Dr. Sirpa Jalkanen, Faron’s co-founders, have been nominated as one of three finalists in the ‘SMEs’ category of prestigious European Patent Office AwardsNominated in recognition of research developing bexmarilimab, an investigational immunotherapy optimising clinical outcomes in cancer treatmentVoting now open for “Popular Prize” award ahead of ceremony on July 9 via dedicated link: Sirpa Jalkanen and Markku Jalkanen | Epo.org TURKU, Finland and BOSTON, May 16, 2024 (GLO

GlobeNewswire 8 months ago

FARON.HE

FARN.L
Faron Confirms Plans for the Coming Months Under New Leadership

Initial data from ongoing Phase 2 part of BEXMAB trial anticipated next monthIncoming CEO, Juho Jalkanen, to accelerate discussions with US regulator to coordinate plans for obtaining marketing approval for MDS patients that have failed HMA TURKU, Finland and BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (“Faron” or the “Company”) (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activa

GlobeNewswire 9 months ago

FARN.L

FARON.HE
Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Key highlights Latest readout of the BEXMAB study shows more responding patients and good durability of remission amongst HR HMA-failed MDS patients.4/5 of the initial Phase 1 HR HMA-failed MDS patients were still alive after eight months of follow-up.While data do not yet allow the precise estimation of median overall survival, the survival benefit seen with the current follow-up already for these 5 first patients is very encouraging. This compares favorably to what has been seen with contempor

GlobeNewswire 10 months ago

FARN.L

FARON.HE
Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

TURKU, Finland and BOSTON, March 14, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today announces it will host a virtual BEXMAB update event on Tuesday, March 19 at 11.00 EET/9am GMT, following the most recent data cut-off and scheduled analysis. Participants of the webcast

GlobeNewswire 10 months ago

FARON.HE

FARN.L
Faron’s Financial Statement Release January 1 to December 31, 2023

TURKU, Finland and BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. ("Faron" or "the Company") (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel myeloid cell targeted immunotherapies, today announced audited full-year financial results for January 1 to December 31, 2023 (the "Period") and provided an overview of recent corporate developments. 2023 Highlights Data from the completed Phase I part of the BEXMAB stu

GlobeNewswire 10 months ago

FARN.L

FARON.HE

Performance Overview

Return	4FR.BE	FTSE 100
YTD	-11.16%	+4.45%
1-Year	-36.71%	+11.10%
3-Year	-46.32%	+13.56%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Faron Pharmaceuticals Oy (4FR.BE)

Faron presents BEXMAB data at ASH Annual Meeting

Faron Pharma secures UK innovation passport for blood cancer immunotherapy

Faron Pharmaceuticals reports positive data from MDS trial

Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024

Faron Confirms Plans for the Coming Months Under New Leadership

Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML

Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab

Faron’s Financial Statement Release January 1 to December 31, 2023

Performance Overview